Brief: Ultimovacs’ UV1 Cancer Vaccine Shows Strong Overall Survival In Malignant Melanoma Phase I Trial

Zelluna ASA

20/06/2022 07:14

June 20 (Reuters) - Ultimovacs ASA  ULTI.OL :
    * ULTIMOVACS’ UV1 CANCER VACCINE SHOWS STRONG OVERALL
SURVIVAL IN
MALIGNANT MELANOMA PHASE I TRIAL
    * ANNOUNCES POSITIVE 2-YEAR OVERALL SURVIVAL DATA IN ITS
ONGOING
PHASE I CLINICAL STUDY OF CANCER VACCINE UV1 IN COMBINATION WITH
PEMBROLIZUMAB FOR TREATMENT OF MALIGNANT MELANOMA
    * ACROSS ALL 30 PATIENTS IN STUDY, 24-MONTH SURVIVAL RATE
WAS 73%

Source text for Eikon:  ID:nGNE6Q08mF 
Further company coverage:  ULTI.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))